Area of research
Pharmacology · Oncology
Research interest
Research interests include Pharmacogenetics and Drug Metabolism, Drug Transport and Resistance Mechanisms, Drug-Induced Hepatotoxicity and Protection, and Analytical Chemistry and Chromatography.
Caution with <scp>PBPK</scp> Modeling Based on the In Vitro Kinetics for Bilirubin Hepatic Uptake and Glucuronidation: Commentary on Dong <i>et al</i>.
Reply to “Minor Contribution of UGT1A1 Inhibition to Atazanavir‐Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data”
Effect of Regular, Low-Dose, Extended-release Morphine on Chronic Breathlessness in Chronic Obstructive Pulmonary Disease
Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping.
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Binding of clozapine to the GABA<sub>B</sub> receptor: clinical and structural insights.
Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab.
Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen
Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.
Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma.
Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202.
Computational Prediction of the Site(s) of Metabolism and Binding Modes of Protein Kinase Inhibitors Metabolized by CYP3A4.
Drug and Chemical Glucosidation by Control Supersomes and Membranes from <i>Spodoptera frugiperda</i> (Sf) 9 Cells: Implications for the Apparent Glucuronidation of Xenobiotics by UDP-glucuronosyltransferase 1A5.
Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity.